Introduction: We studied monocyte transendothelial migration and subsequent polarization into M1/M2 macrophages in response to C-reactive protein (CRP) with two disease-related ligands: (1) phosphocholine (PC) and (2) multilamellar liposomes containing both unoxidized and oxidized forms of the lipid, phosphatidylcholine. These ligands differ in biological origin: PC is present on bacterial cell walls while oxidized lipids are present in atherogenic lipids.
monocyte-to-M2 macrophage/fibroblast maturation that has been predictive and confirmatory of the results seen in our mouse in vivo models of tissue inflammation and fibrosis [4] . In this model, human cardiac microvascular endothelial cells are used as a barrier for mononuclear leukocyte (MNL) transmigration in response to monocyte chemoattractant protein-1 (MCP-1, CCL2).
After transmigration, the monocytes mature sequentially into M1 proinflammatory macrophages followed by M2 anti-inflammatory macrophages with the characteristics of fibroblasts. T cells also migrate, and sequentially differentiate into Th1 followed by a sustained Th2 phenotype. We have previously used this model to demonstrate that two forms of CRP, the native pentamer and the monomer (normally found dissociated from the pentamer by lysophospholipids on a membrane surface), have differing effects on macrophage and T cell differentiation [7] . The native pentamer induced a Th2/M2 response, while the monomer induced a Th1/M1 response. Those studies were performed in the presence of fetal bovine serum in the medium to mimic a serum environment and thus potentially contained undefined lipid or other ligands for the added CRP. In the present study, we eliminated serum and sought to define more rigorously the role of the ligand in the biologic response. We used a serum-free model with added ligands containing phosphocholine (PC, a major ligand for CRP) and multilamellar lipid vesicles containing an oxidized phosphatidylcholine.
Each of these ligands is potentially relevant to human disease. Thirty to forty percent of bacterial species in dental plaque bear PC on their cell walls [8] , and periodontitis has been reported to be a risk factor for myocardial infarction [9] . Streptococcus pneumoniae, which bears PC, causes most cases of community-acquired pneumonia and sepsis. It also invades heart tissue, where it is associated with increased myocardial infarction and heart failure in humans and collagen deposition in animal models [10] . The PC head group is also found on atherogenic-oxidized low density lipoproteins [11, 12] . CRP binds to these oxidized but not native phospholipids, which may bear some relationship to atherogenesis.
We performed these studies with native human mononuclear cells and cardiac microvascular endothelium in which the environment was rigorously controlled. We used a model that emulates in vivo models of inflammation with great fidelity and materials that are contaminant free. We found that (1) CRP alone did not affect monocyte biology but when bound to (2) PC or multilamellar lipids containing oxidized phosphatidylcholine, initiated an M2 response. Surprisingly, despite the similar response with regard to macrophage polarization, the oxidized phospholipid initiated a Th1 response in the T cell population while the PC initiated a Th2 response. Our studies suggest that the difference in the macrophage response to CRP when bound to these different ligands resulted from targeting of different Fcg receptors and was independent of the T cell response. Thus, the response to an oxidized phospholipid, which has been associated with atherosclerosis, initiates an inflammatory Th1 response in T cells; paradoxically, it initiates an anti-inflammatory profibrotic response in macrophage polarization. This may explain some of the controversy regarding mononuclear cell signaling by CRP and its role in atherosclerosis.
Materials and Methods
Reagents RPMI1640 medium was from Invitrogen (Chicago, IL), fetal bovine serum (FBS) was from Hyclone (Pittsburgh, PA), and ITS-X and Brefeldin A were from Sigma-Aldrich (St. Louis, MO). All cytokines, carrier-free CRP (in Tris buffer without any other proteins for stabilization), and blocking constructs were obtained from R&D Systems (Minneapolis, MN). To block the action of IL-13, the recombinant human IL13Ra2/Fc chimeric construct was used at 1 mg, as was a control recombinant human IL-11R/Fc chimeric molecule. Phosphocholine was obtained from Sigma-Aldrich and used at 13 ng/ml. Lipids were obtained from Avanti Polar Lipids (Alabaster, AL) in chloroform, mixed and dried under argon gas in glass tubes with teflon-lined caps, resuspended in 0.01% Tween-20 in PBS and sonicated for 5 minutes at 80 8C in an ultrasonic heated waterbath (Fisher Scientific) to form multilamellar liposomes. We elected to use a sonicating water bath rather than a sonicator probe to avoid foaming and overheating of the sample. The unoxidized lipid was 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC, 30 mg/mL) and the oxidized lipid was 1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine (PAzPC). This partially oxidized lipid was chosen over the fully oxidized lysophosphatidylcholine to limit the conversion of pentameric to monomeric CRP. For fluorescence imaging, the oxidized lipid was the fluorescent 1-palmitoyl-2-{6-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]hexanoyl}-sn-glycero-3-phosphocholine (NBD-PC), used at 1% of the POPC concentration. Omeprazole was obtained from SigmaAldrich, and was activated at pH 5.5 for 30 min before addition at 1:1 (final 100 mM) to cells at pH 7.2. Medium brought to pH 5.5 without the addition of omeprazole was used for the vehicle control. The cells were treated for 1 h with these reagents before use in a TEM assay. Zileuton was obtained from Tocris Bioscience (Minneapolis, MN) and used at 1 mg/mL. The human Fc block, isotype controls, and blocking antibodies against FcgRs CD16/32 (FcgRII/III) and CD32 (FcgRII) were obtained from BD Pharmingen (San Diego, CA), against CD64 (FcgRI) from eBioscience (San Diego, CA), against the R131 variant of FcgRII (clone 41H16 hybridoma) from Dr. Ted Zipf (MD Anderson Cancer Center, Houston, TX, retired) and their F(ab') 2 fragments purified (Pierce F(ab') 2 Preparation kit, Thermo Scientific, Pittsburgh, PA) before addition at 10 mg per well. Intravenous gammaglobulin (Venoglobulin-S 5% solution) was obtained from Alpha Therapeutic Corporation (Los Angeles, CA).
In vitro transendothelial migration (TEM)
As detailed previously [2, 13] , blood was obtained from healthy volunteers under a protocol approved by the Institutional Review Board of Baylor College of Medicine. ACD (Sigma) anticoagulated blood was fractionated by Ficol-Hypaque gradient centrifugation (Histopaque-1077; Sigma) to collect mononuclear cells (MNL). For a TEM assay, human cardiac microvascular endothelial cells (HCMEC) (Lonza (Walkersville, MD), passages 4-9) were seeded onto an insert coated with human collagen type IV (Millipore, Temecula, CA). Human MNL (in RPMI1640 with 10% FBS and antibiotic-antimycotic (Invitrogen) or without serum but with ITS-X (Sigma-Aldrich)) were then added to each insert and the same medium including 650 ng/ mL MCP-1 for chemoattraction was added to the well below and the indicated stimuli to the insert. MNL were allowed to migrate for 16 or 96 h before fixing and counting the cells on the bottom of the well. At the end of each migration period, the migrated cells were harvested immediately for RNA or, for protein, after 6 h of exposure to Brefeldin A (Sigma).
Immunofluorescence
Cells that transmigrated through an endothelial barrier were allowed to attach to poly D-lysine-coated coverslips (NeuVitro, Vancouver, WA) at the bottom of the lower well. The cells were fixed and stained with mouse anti-CD86 (BioLegend, San Diego, CA), MRP-14 (S100A9, BioLegend) or rabbit anti-CD206 (Epitomics, Burlingame, CA). For staining of intracellular IL-13, the cells were allowed to migrate onto coverslips for 7 h and then incubated for 16 h with Brefeldin A at 10 mg/mL. At the end of the incubation, the cells were stained with anti-CD11b-FITC (BD Pharmingen, San Jose, CA), washed and treated according to directions for the BD Fix-Perm kit, with intracellular staining of IL-13 (anti-IL-13-PE, BD Pharmingen). After all staining procedures, the coverslips were mounted with the cell nucleus stain DAPI. Microscopy was performed on an Olympus AX70 using a QImaging Retiga 2000R camera. Colors were assigned and merged using ImageJ software (version 1.46r, NIH). For cytometry, cells were stained with antibodies against CD3 and CD4 (Becton Dickinson, Franklin Lakes, NJ), CD294 (CRTH2, BioLegend), FOXP3 (eBioscience), and IL-1R1 and IL-1R4 (R&D Systems). Intracellular antigens were stained by use of the Foxp3 Transcription Factor Staining Buffer Set (eBioscience, San Diego, CA). Cells were analyzed on a Cell Lab Quanta SC flow cytometer (Beckman Coulter, Miami, FL) using the Quanta Analysis software and FlowJo software (Tree Star Inc., Ashland, OR). Gating was based on comparisons of signals from the listed antibodies compared with isotype control antibodies, wherein gates were set at 1% or less of the negative control for evaluation of positive antibodies.
Characterization of liposomes
For transmission electron microscopy, liposomes were prepared and then collected on lacey carbon copper grids (300 mesh, EMS Sciences, Hatfield, PA). After 20 min, the grids were rinsed in three changes of water. The liposomes were then fixed in 5% ionic fluid (Hitachi, Ltd, Tokyo, Japan) and rinsed five times in water. A post-fix composed of 4% aqueous osmium tetroxide (EMS, EM grade) was applied for 10 min after which the samples were air-dried. Samples were viewed on a Hitachi H7500 transmission electron microscope and images were captured using an AMT XR-16 camera run by AMT Image Capture, v602.600.51 software. The accelerating voltage was 80 kV. Some samples were treated as above, but were then stained in 2% aqueous uranyl acetate. Grids alone and grids treated in the same fashion with the detergent buffer but no liposomes were used to compare for identification purposes (data not shown).
For size distribution measurements, liposomes were placed into a Zetasizer instrument (Malvern Instruments, LTS., Malvern, UK).
Protein array
Cells were harvested and protein was isolated using Cell Lysis Buffer (RayBiotech, Norcross, GA) supplemented with Halt Protease and Phosphatase Inhibitor Cocktail (Thermo Scientific). The protein preparation (250 mg) was loaded onto human cytokine antibody array membranes (R&D Systems). Membranes were processed according to the manufacturer's instructions, images on film were scanned, and densitometry was measured by ImageJ software. Data are expressed as integrated pixel density normalized to the positive plate controls and with the background subtracted.
ELISA
Culture supernatants from cells 4 days post-TEM were collected and concentrated sevenfold using 5000 MW cutoff columns (Sartorius, Goettingen, Germany). The supernatants were assayed for IL-10 and TGF-b using high sensitivity ELISA kits from RayBiotech.
RNA isolation and transcriptional expression
For each donor set, there was a control group made up of MNLs that were cultured with the activators phorbol myristate acetate and calcium ionomycin for 3 days but had no contact with the TEM model. These samples expressed all gene products listed, so that the experimental samples could be compared to a donor-specific positive control (% of control as listed in the figures).
Total RNA was isolated with TRIzol reagent (Life Technologies). Complimentary DNA was synthesized from 1 mg of RNA with a Verso cDNA synthesis kit (Thermo Scientific) using random hexamer and oligo-dT primers (3:1). Real-time PCR amplification reactions were performed with SsoAdvanced SYBR Green Supermix (BioRad, Hercules, CA) in triplicate using a CFX96 thermal cycler (BioRad). Cycling conditions (annealing temperature) were optimized for each primer pair. Gene expression was measured by the DDCT method and was normalized to HPRT RNA levels. Primers were designed and evaluated according to MIQE guidelines [14] . 
In-cell Western assay
MNLs were placed into a 96-well plate at 3 Â 10 5 in serum-free RPMI1640 and allowed to adhere for 1 h before stimulation with CRP (5 mg), PC (12 ng), or liposomes (30 mg) singly or in combination. Two minutes after stimulation, the cells were fixed and processed with the In-Cell Western Assay Kits I and II (LI-COR, Lincoln, NE) using primary antibodies against phospho-SYK (Tyr323) and total SYK (Cell Signaling, Boston, MA) at 1:200 and the IRDye 800CW-labeled secondary antibody (from the kit) at 1:500. Plates were read on an Odyssey Infrared Imaging System (LI-COR) using the Sapphire700 dye for cell number normalization.
Statistical analysis
All data are expressed as mean AE SE. Since data were not always normally distributed, the nonparametric Mann-Whitney U-test was used for comparison of two data sets, whereas the Tukey-Kramer Multiple Comparisons Test was used for more than two. A p-value <0.05 was considered statistically significant.
Results

M2 macrophage differentiation after TEM with phosphocholine and CRP
In a TEM assay that used medium with serum, a wide range of CRP concentrations promoted M2 differentiation, with no significant differences between doses, indicating the possibility of saturating the system at low doses but without toxicity or other adverse consequences at higher doses (Fig. 1a) . Since serum may contain CRP ligands, we tested the hypothesis that ligand binding permits or enhances the M2-promoting potential of CRP. We performed the TEM assay using serum-free medium and 5 mg/mL of CRP (in the low range used in the experiments in Fig. 1a) , and added the most chemically simple ligand known for CRP, phosphocholine (PC, phosphorylcholine, structure shown in Fig. 1b inset) [15] . At equimolar concentrations, each component alone showed no significant activity, but the combination demonstrated increased activity (Fig. 1b) .
M2 macrophage differentiation after TEM with liposomes and CRP
Because CRP can bind to the PC moiety on more complex molecules such as lipids, we tested multilamellar liposomes, with and without CRP, in the TEM assay. To model the effect of lipid oxidation in a defined way, we incorporated small amounts of an oxidized phospholipid with a PC head group (PAzPC) into the liposomes with an unoxidized lipid (phosphatidylcholine, POPC; structures shown in Fig. 1c ) to make a reproducible defined reagent. The liposomes incorporating the oxidized lipid at various concentrations suppressed monocyte fibroblast differentiation, and that was opposed by the addition of CRP for all concentrations (Fig. 1d) . The combination of CRP with the oxidized lipid at some concentrations also increased the number of monocytic fibroblasts over background, as was observed for the combination of CRP and PC (Fig. 1b) . All further experiments were done with liposomes formed of POPC and 1% PAzPC. Their mean size was 139 AE 1.7 nm and their index of polydispersity was 0.3 AE 0.01 (see Supplementary  Fig. S1a ), a size range optimal for phagocytosis (reviewed in Refs. [16, 17] ). Transmission electron microscopy showed them to be round to ovoid structures with typical lipid osmium staining and uranyl acetate shadowing in the size range 50-200 nm ( Supplementary Fig. S1b and c) . Liposomes, when made with a fluorescent-oxidized lipid (NBD-PC), could be seen internalized by macrophages ( Supplementary Fig. S1d ).
Liposomes containing oxidized lipids promote M2 macrophage differentiation in the presence of CRP
To characterize the differentiation of the macrophages treated with liposomes with and without CRP, we stained them by immunofluorescence for markers of M1 or M2 macrophages [18] . Within 16 h after the initiation of transmigration, all of the transmigrated macrophages under both conditions were in an M1 state as indicated by staining with antibodies against the markers CD86 and MRP14 (S100A9) (Fig. 2a and b) . At the 4-day harvest time, the liposome only treated transmigrated macrophages were still in the M1 state ( Fig. 2c and e) , but most macrophages treated with both liposomes and CRP were in an M2 phenotype, with a CD86 neg CD206 þ phenotype and a spindle shape with an oval nucleus ( Fig. 2d and f) . We have previously reported that these cells are positive for the fibroblast markers collagen type I, prolylhydroxylase, and discoidin domain receptor 2, a receptor for collagen [3, 4, 13] . We further defined the status of the macrophages by testing for the gene expression levels of factors associated with M1 versus M2 differentiation. The data are expressed as the percent of gene expression in a control population of cells from the same donor activated with phorbol myristate acetate and calcium ionomycin (designated as 100%). We employed this method to ensure measurable levels of mRNA for each gene in our control preparations. We measured the mRNA levels of NOS2 (INOS), an M1 marker [19, 20] , in 4-day migrated cells treated with the indicated reagents, and found that CRP reduced the levels seen in cells treated with PC or liposomes (lipid, Fig. 3a and b) . The levels of arginase 1 (ARG1, an M2 marker [21] [22] [23] ), by contrast, were increased by CRP (Fig. 3c and d) , confirming the results from microscopy ( Fig. 2) .
Because M2 macrophages are associated with an antiinflammatory influence only under some conditions [18] , we measured the levels of an anti-inflammatory agent made by macrophages, IL-1 receptor antagonist (IL-1RA) [24] in the response to liposomes. The levels in the liposome-treated cultures were low (Fig. 4a) , even lower than those for untreated samples (Fig. 4b) , perhaps because of the proinflammatory effect of this treatment. The addition of CRP significantly increased those levels, even above the control (Fig. 4a and b) .
IL-13 signaling is critical for CRP-induced M2 maturation
We reported that IL-13 promotes the differentiation of monocytes into M2 fibroblasts after TEM [4] , so we investigated the presence of this cytokine in the CRP model. We measured mRNA levels of IL-13 in cells under various treatments, and found that there was an increase with CRP whether the treatment was with PC (Fig. 5a ) or liposomes (Fig. 5b) . The data were expressed as a percent of the amount found in mitogen-activated controls, a theoretical maximum positive control. To prove the role of IL-13 in the monocyte differentiation, we used blocking agents against IL-13 in the TEM assay. We used a chimeric molecule composed of the IL-13 receptor a2 (IL-13Ra2) plus the Fc portion of IgG (shown as 13R) to sequester secreted IL-13 in the model. A similarly engineered chimera of the IL-11 receptor was used as a control (shown as 11R). Interestingly, the IL-13 block decreased even the background levels of M2 macrophages (Fig. 5c) , as well as decreasing the enhanced numbers induced by CRP. With liposome treatment, the expected decrease in M2 numbers was seen, and this was countered by both CRP and recombinant IL-13 (Fig. 5d) . The CRP effect was blocked by 13R down to the level of liposome treatment only. We also used several drugs known to block the effects of IL-13, the proton pump inhibitor omeprazole [25] and the leukotriene inhibitor zileuton [26, 27] . Both inhibited, to different degrees, the numbers of M2 macrophages seen with CRP plus FBS (see Supplementary Figs. S2a and b) . The combination of omeprazole and zileuton produced no additive effect (see Supplementary Fig. S2c) . We next investigated possible origins of the generated IL-13.
Immunofluorescence of migrated adherent cells migrated for 24 h revealed CD11b þ cells accumulating cytoplasmic IL-13 protein after 16 h of Brefeldin A treatment (see Supplementary Fig. S3 ).
T cell responses are not required for the observed M2 maturation IL-13 can also derive from a type 2 lymphocyte immune response [28] [29] [30] , and therefore we investigated T cell subsets present in this model. We assessed gene expression of TBET for Th1 cells [31] and GATA3 for Th2 and other type 2 cells [32] [33] [34] [35] . We found no differences in gene expression of TBET with CRP treatment, although the levels were much higher than controls in cells treated with liposomes than with PC ( Fig. 6a and b) . With respect to GATA3, a dramatic increase with CRP added to PC (Fig. 6c) was not matched by any increase with CRP added to liposomes (Fig. 6d) . Further confirmation of the lack of an increased type 2 response when liposomes were present was obtained by flow cytometry of cells harvested from the TEM assay. We used antibodies against CD294 (CRTH2, Fig. 7a ) and IL-1 receptor 4 (IL-1R4, Fig. 7b ) to assess Th2 cells [36, 37] and found low numbers in liposome-treated cultures (equivalent to those found in peripheral blood), and these were not increased by the addition of CRP. Representative histograms of these and other T cell markers are shown in Supplementary Figure S5a Another way in which an anti-inflammatory state can be promoted is via regulatory T cells (Treg) cells, and so mRNA levels were measured for the Treg transcription factor FOXP3 [38] , which did not change with the addition of CRP to liposomes (see Supplementary Fig. S4a ). We also measured the number of CD4 þ FOXP3 þ cells by cytometry;
this did not change with CRP (see Supplementary Fig. S4b ), and none of the FOXP3 þ cells were positive for TGF-b (data not shown). We measured the numbers of cells positive for IL-1 receptor 1 (IL-1R1) [39] and again saw no difference with CRP (see Supplementary Fig. S4c ). Finally, we measured by ELISA several Treg-associated anti-inflammatory cytokines released into the culture supernatant. No positive signal was obtained for TGF-b. IL-10 was found in the supernatants, but not differently with CRP (see Supplementary Fig. S4d ).
Signaling via FcgR is critical for the observed M2 differentiation but varies with CRP ligand
Since T cell responses could not explain the effects of CRP on the liposome response, and indeed should have opposed it, we sought a mechanism for M2 differentiation that could be T cell independent. Since CRP has been reported to bind to IgG Fc receptors [40] , we used antibodies against FcgR to block the observed effects of CRP. All of the blocking antibodies were made into F(ab') 2 fragments to keep their antigen-binding sites intact but prevent any interaction with FcgR through their Fc portions. We used human Fc block as a positive control to stop interactions with all FcgR, and antibodies specific for one or more FcgR to block individual types. This included clone 41H16, an antibody directed against the R131 variant in FcgRII [41] that binds CRP preferentially compared with H131 (which binds IgG2 preferentially) [42] . When these antibodies were used, the response to PC plus CRP was blocked only by the antibody against FcgRI (CD64, Fig. 8a ). However, this antibody had no effect on the response against liposomes plus CRP, in which the blocking agents targeting FcgRII (CD32) were effective (Fig. 8b) . To test if the interactions of the CRPligand combinations resulted in cell signaling, we measured the level of phosphorylation of SYK, a kinase downstream of activating FcgRs [43] . The complexes of CRP with either PC or liposomes were particularly effective in accomplishing SYK phosphorylation (Fig. 8c) . As with CRP, the addition of intravenous gamma globulin (IVIG) also opposed the suppression of M2 differentiation by liposomes (Fig. 8d) . 
Endothelial cell signaling is not critical for M2 maturation
Since CRP is reported to interact with endothelial cells, we asked if those cells present in this system could have contributed to the observed results via FcgRII activation. We measured binding of the 41H16 antibody to the endothelial cells used in the cultures and the monocytes in our MNL preparations. No binding of the antibody was seen to the endothelial cells by flow cytometry (see Supplementary   Fig. S6a ), whereas the monocytes were positive (see Supplementary Fig. S6b ). All donors used for these experiments were positive for 41H16 binding (data not shown).
Discussion
We have previously reported that our human in vitro model of M2 macrophage differentiation gives comparable findings to our mouse in vivo models of cardiac inflammation and fibrosis mediated by monocyte-derived M2 macrophage/ fibroblasts [1] [2] [3] . Our finding here that CRP increased M2 differentiation into fibroblasts contrasts with our previous studies that SAP, a similar pentraxin, had the opposite effect [2] . Indeed, in humans, SAP is anti-fibrotic [44, 45] , which is consistent with our results in the mouse and in our human in vitro model. Although both pentraxins bind to FcgRs, these disparate effects have been reported to be due to the ability of SAP to inhibit fibrosis via dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN/CD209), to which CRP does not bind [46] . Other reports about the effects of CRP on fibrosis, inflammation, atherogenesis, cardiovascular disease, and monocyte/macrophage responses are conflicting (possible reasons for which are reviewed in Scirica and Morrow [47] ). Some of these reasons are the manner of CRP preparation, level of administration, contaminants, and animal models. We elected to use a simplified system that bypassed these issues by using a recombinant CRP preparation from mammalian cells to avoid (1) bacterial products, (2) the presence of ligands that might co-purify with the CRP (as from biological fluids), and (3) damage to the molecule such as dissociation or aggregation, and (4) the presence of complement, all of which could cause this reagent to have varying biological effects. This system also employed human cells and allowed serum-free conditions so that defined ligands for CRP could be tested. An accelerated conversion of monocytes to polarized macrophages has always been observed in this model, and that allowed the elimination of serum, with its constituent immunoglobulins (binding to Fc receptors), CRP-binding moieties, and microparticles capable of converting pentameric to monomeric CRP. Using contaminant free materials, we showed that CRP alone had no effect on M2 macrophage differentiation when used in a medium without serum. When combined with PC or phosphatidylcholine-containing liposomes, that effect was highly promoted. Since CRP binds PC or other ligands on one face of the pentamer and FcgRs on the other face, it can bridge these molecules [11, 48, 49] . These results indicate that either the avidity of interaction of CRP with FcgR or its affinity for individual FcgR may be increased by occupation of its opposite side with a PC-containing ligand. 
Role of lipid oxidation
An important finding was that, while unoxidized phosphatidylcholine had no effect in this system, liposomes formed of the unoxidized form (POPC) with varying amounts of an oxidized form (PAzPC) depressed the background level of M2 macrophages, which was at least countered by CRP. Additionally, under conditions of molar equivalence with PAzPC, CRP addition led to the same increase in M2 macrophages as it did with PC. CRP only binds to the charged head group (PC) of a phospholipid when the lipid is oxidized [12] , which explains its lack of an effect with the unoxidized POPC.
Transition from an M1 to an M2 response can be incongruent with the T cell response
We characterized the cells undergoing monocyte differentiation to an M2 phenotype in this system and reproduced our previous findings that an early M1 response was followed by a later M2 response [50] . That the M2 response in the present case was anti-inflammatory was confirmed by the increased production of IL-1RA. That it was mediated by the profibrotic cytokine IL-13 (as previously noted by us and others [4, 51] ) was shown by mRNA levels and blocking experiments. We identified CD11b þ macrophages as one source for the IL-13, introducing the possibility of an autocrine response. Although the contribution of IL-13 is usually associated with a Th2 response, we were surprised to find that, although we found increased levels of the Th2 transcription factor GATA3 in response to PC plus CRP, there was no such response to liposomes plus CRP. FcgR signaling specificity is dependent on the species of CRP ligand
These results indicate that CRP induces anti-inflammatory M2 differentiation despite a chronic Th1 response and relative failure of a Th2 response to liposomes containing oxidized lipids. We sought to explain the mechanism of M2 differentiation in the face of a proinflammatory T cell response, and investigated the role of CRP signaling via FcgR. We used blocking antibodies against individual FcgR and discovered that the CRP effect with PC was conveyed through FcgRI, whereas the response to CRP with liposomes was mediated through FcgRII. That these were both activating events was confirmed by the phosphorylation of SYK, an event downstream of activating FcgR (FcgRI and FcgRIIa) occupation [43] . The differential activation of FcgRI or FcgRII by CRP with PC versus liposomes may be analogous to the higher affinity/avidity binding of monomeric immunoglobulin by FcgRI and immune complexes by FcgRII. In the case of CRP, its binding of the small molecule PC would not lead to complex formation, whereas its binding to the liposome at multiple sites could increase its avidity for FcgRII. These data indicate that the binding of CRP to ligands and subsequent activation of FcgR may be solely responsible for the monocyte differentiation seen in this model. It has been reported that CRP binding to the fully oxidized lipid lysophosphatidylcholine impairs its affinity for FcgR, but maximum binding capacity was unchanged in that study, and subsequent signaling was not determined [52] . In our study, we elected to use a less-oxidized phosphatidylcholine (PAzPC) to avoid the detergent effects of lysophosphatidylcholine (and possible conversion of the pentameric to monomeric CRP) and to better approximate the degree of oxidation that may occur in vivo.
Disparate macrophage and T cell responses
We have already reported the correspondence of our model to our studies of cardiac fibrosis in the mouse [1] [2] [3] . Here, we refined the TEM assay to permit the investigation of precise molecular configurations and cell subset analyses. It has been reported that oxidized lipids promote a proinflammatory Th1 and M1 response [53, 54] . What is surprising is that CRP could shift the monocyte response to an M2 phenotype without affecting that T cell response. M2 macrophages have been observed to direct T cell activation and maturation [55] , and so we expected a change from a Th1 to a Th2 response in cultures with CRP, especially since CRP has been reported to suppress Th1 cell differentiation [56] . Others have shown that oxidized lipids induce maturation of na€ve T cells to Th1 cells [57] ; thus it is possible that the Th1 response could become chronic or predominant based on continuous recruitment of new cells to a proinflammatory phenotype (Fig. 9) . Given the independence of T cell and macrophage responses noted here, however, inflammation and fibrosis could coexist, as has been noted in atheromas [58, 59] .
CRP may be relevant to both infection and sterile inflammation in atherosclerosis. Viable bacteria, including members of the oral, skin, and gastrointestinal flora, have been cultured from atheromas [60] . Genomic analysis indicates the possibility of bacterial translocation between periodontal pockets and coronary arteries [61, 62] and there are differences in microbiota between symptomatic and asymptomatic plaques [63] . Monocytes that engulfed bacteria are postulated to be the source of the translocation [61] , and CRP may play a role in that process for PCbearing bacterial species. Our results here open the possibility that bacterial engulfment, depending on the receptors involved, may not result in a uniform or chronic proinflammatory response, but one that may develop into an anti-inflammatory profibrotic phenotype.
Potential pertinence to atherosclerotic cardiovascular disease
Macrophages take up oxidized lipids by a variety of receptors, including via CRP if the lipids bear PC. The resultant formation of foam cells may include their conversion into a pro-fibrotic phenotype [64] as we have shown here. In that way and others, macrophages may be important effectors of the pathologic stages in atherosclerosis. While CRP is a commonly used biomarker for cardiovascular disease, its mechanistic link to the control of stability or lability in atherosclerotic plaques is not well defined. We do not presume to solve this issue. However, it should be noted that the CRP-mediated effects described herein do not require T cell direction and result from interaction of ligand-bound CRP with FcgR. The supply of these ligands is compatible with a chronic environmental exposure yielding an innate immune response. The resultant fibrosis in tissues would theoretically be an evolutionarily derived protective strategy.
Overall, these data from a simplified system indicate that, while CRP unbound to ligands may not have a significant effect on leukocyte biology, the type of ligand bound to it may be an important or even crucial factor in the clearance of complexes and the subsequent immune response. We have presented data from two different CRP ligands, phosphocholine and an oxidized phosphatidylcholine lipid, with different outcomes from each. PC and oxidized lipids arise from different origins, both of which have been linked to atherosclerosis via infections and/or lipid disorders. Although CRP-related events occurring in vivo may be much more complex, this model presents a way to dissect molecular and cellular events that lead to fibrosis, a common component of many human disease states.
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